A Retrospective Cohort Study to Determine Real-World Treatment Patterns in Patients with Sézary Syndrome in the United States
Some systemic therapies showed decreased usage over time while a few showed increased utilization, with mogamulizumab showing the largest increase. Treatment patterns for SS varied by region. Further research is needed to examine the factors that drive treatment selection for patients with SS.
Authors
- Eslie Dennis (ORCID: https://orcid.org/0000-0002-4708-7612)
- Chunlan Chang
- Robert Ristuccia
- Takeshi Takahashi (ORCID: https://orcid.org/0000-0002-3898-5883)
- Oleg E. Akilov (ORCID: https://orcid.org/0000-0003-1339-5710)
- Yang Zhao (ORCID: https://orcid.org/0000-0003-1444-5927)
- Huanxue Zhou
- Takanobu Nomura
Institutions
- Kyowa Kirin (Japan) (JP)
- Veterans Health Administration (US)
- Axsome Therapeutics (United States) (US)
- University of Pittsburgh Medical Center (US)
- Kyowa Kirin (France) (FR)
- Kirin (United States) (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2024-09-21
- DOI
- https://doi.org/10.1007/s40487-024-00306-2
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kyowa Kirin Pharmaceutical Development